-
Correlation of Intermediate Clinical Endpoints (ICES) For Overall Survival (OS) In Localized or Locally Advanced Prostate Cancer (LPC/LAPC): Analysis of Individual Real-World Data (RWD)
Sep 9, 2025, 16:22 PM -
US Population-Level Clinical Impact of Lorlatinib Treatment on ALK+ Metastatic Non-Small Cell Lung Cancer Outcomes
Sep 9, 2025, 16:22 PM -
Ten Years of Portugal’s HTA System Through Stakeholder Eyes: Reflections and Future Priorities
Sep 9, 2025, 16:22 PM -
A Comparative Analysis of Similarities and Differences of RWE Standards Across Regulatory and Health Technology Assessment Bodies
Sep 9, 2025, 16:22 PM -
Rising Costs in Pharmaceutical Services: A Decade of Prescription Spending Trends in Türkiye 2015-2024
Sep 9, 2025, 16:22 PM -
A Person-Centered Approach: Exploring Social Support Network and Mental Health Among Shoebox House Residents in Hong Kong
Sep 9, 2025, 16:22 PM -
Guidelines for Health Technology Assessment Ministry of Health Sultanate of Oman
Sep 9, 2025, 16:22 PM -
Measuring Health-Related Quality of Life and Food Insecurity in the General Population in Lebanon During the Third Worst Socioeconomic Crisis in History
Sep 9, 2025, 16:22 PM -
Analysis of Social and Economic Burden of Type 1 Diabetes Care in Italy
Sep 9, 2025, 16:22 PM -
Improving Colorectal Cancer Surgical Outcomes Through Audit and Feedback: Results From the Emilia Romagna ESCA Program
Sep 9, 2025, 16:22 PM -
Price Implications of the Most-Favored Nation Policy on US Oncology Drug Prices
Sep 9, 2025, 16:22 PM -
The Societal Value of Lecanemab for Patients With Early Alzheimer's Disease in Japan
Sep 9, 2025, 16:22 PM -
Dealing With Missing Data in Health Economic Studies of Small to Moderate Size: How to Minimize Bias
Sep 9, 2025, 16:22 PM -
Comparative Prevalence of Suicidal Ideation and Self-Harm History: Rexulti vs. Other Oral Atypical Antipsychotics
Sep 9, 2025, 16:22 PM -
Cost Variation Across Lung-Cancer Diagnostic-Pathway Clusters: A Nationwide Real-World Analysis of 18,569 French Patients
Sep 9, 2025, 16:22 PM -
Analysis of Historical European Medicines Agency (EMA) Marketing Authorization (MA) Timelines: Will EU Joint Clinical Assessment (JCA) Timelines Be Longer Than Expected?
Sep 9, 2025, 16:22 PM -
Healthcare Resource Utilization in Patients With Non-Small Cell Lung Cancer (NSCLC) and Epidermal Growth Factor Receptor Mutation (eGFRm): A Retrospective Cohort Study in a Portuguese Comprehensive Cancer Center
Sep 9, 2025, 16:22 PM -
Impact of Comparator Type on Cost-Effectiveness Outcomes: Insights From ASMR III Evaluations in France
Sep 9, 2025, 16:22 PM -
Productivity Costs Due to Respiratory Infections in Denmark: A Potential for Prophylaxis
Sep 9, 2025, 16:22 PM -
Developing Best Practice for Using Automation Tools in Literature Reviews
Sep 9, 2025, 16:22 PM
